VTGN (Vistagen Therapeutics) ROCE %: -153.20% (As of Mar. 2026)


VTGN Vistagen Therapeutics Inc VTGN
40 GF Score
Price $0.67
GF Value $2.20
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Vistagen Therapeutics ROCE %?

Vistagen Therapeutics VTGN +5.14% 40 ROCE % is -153.20% as of Mar. 2026. GuruFocus rates VTGN with a GF Score™ of 40/100 and a GF Value™ of $2.20 (Possible Value Trap). The stock has 3 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Vistagen Therapeutics's annualized ROCE % for the quarter that ended in Mar. 2026 was -153.20%.

Vistagen Therapeutics  (NAS:VTGN) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Vistagen Therapeutics ROCE % Related Terms

Vistagen Therapeutics ROCE % Historical Data

* Premium members only.

The historical data trend for Vistagen Therapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vistagen Therapeutics ROCE % Chart

Vistagen Therapeutics Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -55.22 -138.81 -48.90 -58.84 -134.19

Vistagen Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -75.10 -97.63 -128.28 -131.61 -153.20
VTGN
40GF Score
Vistagen Therapeutics Inc VTGN
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vistagen Therapeutics ROCE % Calculation

Vistagen Therapeutics's annualized ROCE % for the fiscal year that ended in Mar. 2026 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=-72.126/( ( (84.341 - 12.612) + (48.564 - 12.795) )/ 2 )
=-72.126/( (71.729+35.769)/ 2 )
=-72.126/53.749
=-134.19 %

Vistagen Therapeutics's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-66.868/( ( (65.056 - 13.529) + (48.564 - 12.795) )/ 2 )
=-66.868/( ( 51.527 + 35.769 )/ 2 )
=-66.868/43.648
=-153.20 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -153.20% mean?
Vistagen Therapeutics (VTGN) has a ROCE % of -153.20% as of Mar. 2026.
Is Vistagen Therapeutics' ROCE % too high?
Vistagen Therapeutics' current ROCE % is -153.20%. Overall, Vistagen Therapeutics has a GF Score™ of 40/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Vistagen Therapeutics' ROCE % compare to PLUR and PTN?
Vistagen Therapeutics' ROCE % of -153.20% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Vistagen Therapeutics's current ROCE % is -153.20%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vistagen Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Vistagen Therapeutics (VTGN) is currently considered Possible Value Trap. The stock's GF Value™ is $2.20, compared to a current price of $0.67 — trading 69.7% below its estimated fair value. The current ROCE % is -153.20%. Vistagen Therapeutics' overall GF Score™ is 40/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Vistagen Therapeutics (VTGN), the current ROCE % is -153.20% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vistagen Therapeutics (VTGN) Overvalued in 2026?

Based on GuruFocus' analysis, Vistagen Therapeutics stock appears to be undervalued. The current stock price of $0.67 is trading 69.7% below its estimated GF Value™ of $2.20. GuruFocus considers Vistagen Therapeutics to be Possible Value Trap.

Key valuation signals for VTGN:

  • ROCE %: -153.20%
  • GF Value™: $2.20 vs. price of $0.67 (69.7% below fair value)
  • GF Score™: 40/100 with 3 warning signs

No single metric tells the full story. See the VTGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vistagen Therapeutics Business Description

Address 343 Allerton Avenue, South San Francisco, CA, USA, 94080
Vistagen Therapeutics Inc is a late clinical-stage therapeutics company focused on developing and commercializing medicines for patients with social anxiety disorder, depression, menopausal hot flashes, psychomotor impairment due to mental fatigue, and cancer cachexia. The company is engaged in developing intranasal product candidates called pherines, which leverage the understanding of nose-to-brain neurocircuitry. Vistagen's pherine pipeline consists of various product candidates like: Fasedienol, Itruvone, PH15, Refisolone, and PH284, which are being developed to provide treatment for a variety of disorders. Additionally, it is seeking potential partners for the further clinical development and commercialization of an oral drug candidate, AV-101, to treat certain neurological disorders.
40GF Score

Get the complete analysis for VTGN

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.67
Price
$2.20
GF Value